BOSTON SCIENTIFIC LIMITED

Their core work

Boston Scientific is a global medical device manufacturer with a major R&D hub in Galway, Ireland, specializing in implantable devices for cardiovascular, diabetes, and neurological conditions. Within H2020, they contribute industry-grade expertise in biocompatible materials, micro-fabricated medical devices, and advanced manufacturing processes to translate academic research toward clinical application. Their involvement spans from graphene-based biomedical technologies to computational modelling of implantable devices and bioresorbable materials for vascular and orthopaedic use. As an end-user of research outputs, they bring real-world device design constraints and regulatory awareness to research consortia.

What they specialise in

How they've shifted over time

In the early period (2015-2018), Boston Scientific's H2020 engagement was broadly spread across graphene-based materials research, manufacturing process optimization, and workforce training — reflecting a technology-scouting posture across multiple fronts. From 2019 onward, their focus sharpened decisively toward therapeutic applications: diabetes treatment (DELIVER), cardiac tissue engineering (BRAV3), micro-robotics for health (UWIPOM2), and translating graphene research toward pilot-line manufacturing (2D-EPL). This shift signals a move from upstream materials exploration toward downstream clinical device development and personalized medicine.

Boston Scientific is converging on personalized implantable therapies — combining biomaterials, computational modelling, and 3D printing — making them an ideal industry partner for translational biomedical projects.

How they like to work

Boston Scientific exclusively participates as a consortium partner, never as coordinator — consistent with a large industry player contributing domain expertise and end-user validation rather than managing project administration. With 337 unique partners across 25 countries, they operate as a broad-network collaborator open to diverse consortia rather than returning to the same small group. Their role is typically that of an industry end-user who grounds academic research in real-world device requirements and manufacturing feasibility.

Extremely well-connected with 337 unique consortium partners spanning 25 countries, reflecting the breadth of the Graphene Flagship and multiple large RIA consortia. Their network covers academic research groups, clinical partners, and advanced manufacturing specialists across Europe.

What sets them apart

As one of the world's largest medical device companies with a dedicated Irish R&D centre, Boston Scientific brings something few academic or SME partners can: a direct path from research prototype to commercially manufactured, regulatory-compliant medical device. Their simultaneous involvement in the Graphene Flagship and multiple disease-specific projects (diabetes, cardiac, MS) means they can cross-pollinate materials breakthroughs with clinical applications. For consortium builders, they offer industry credibility, manufacturing scale-up capability, and an understanding of what it takes to bring a lab concept through to a patient.

Highlights from their portfolio

• OPTOGENERAPY
  Largest single EC contribution (EUR 805,880) — applying optogenetic protein therapy to multiple sclerosis, an unusual intersection of photonics and neurology for a device company.
• BRAV3
  Combines computational biomechanics, hiPSC-derived cardiac tissue, and 3D printing for personalized bioprosthetic valves — represents their most forward-looking translational work.
• GrapheneCore2
  Part of the EU's billion-euro Graphene Flagship, positioning Boston Scientific at the forefront of 2D material applications in biomedical devices and sensors.